DREAMORO VENTURES
Specialist capital for the companies reshaping healthcare
Dreamoro Ventures is a specialist healthtech venture capital fund investing at pre-seed to Series A. We back founders building technology-enabled health companies across the full value chain, with a deliberate weighting toward prevention and early intervention.
OUR APPROACH
Conviction-led investing in a sector we know deeply
We're not generalists who dabble in health. Every partner, advisor, and LP in our network has deep domain expertise in healthcare, technology, or both.
This means we can move faster on opportunities, provide more relevant support, and build a portfolio with genuine thematic coherence.
FOCUS AREAS
Where we invest
Prevention & Wellness
Companies that intervene before disease progresses, including chronic disease management, mental health, and preventive diagnostics.
AI-Enabled Health
AI and machine learning applied to clinical decision support, drug discovery, medical imaging, and operational efficiency.
Digital Therapeutics
Software-based interventions that deliver evidence-based therapy, often regulated as medical devices.
Diagnostics & Monitoring
Remote patient monitoring, point-of-care diagnostics, and wearable health technology.
Health Infrastructure
Platforms that improve healthcare delivery, including telehealth, care coordination, and clinical workflow automation.
Genomics & Precision
Personalised medicine, genomic testing, and precision health approaches.
FUND STRUCTURE
Built for the stage where specialist capital matters most
At pre-seed and seed, the investor-founder relationship is disproportionately important. We bring more than capital.
WHAT WE BRING
More than capital
Operator Experience
We've built and scaled healthtech companies. We understand the regulatory, clinical, and commercial challenges founders face.
Ecosystem Access
Deep collaborations with LX Health, UNSW Founders, and Swinburne give our portfolio companies access to deal flow, pilots, and co-investment.
Studio Capability
Through Dreamoro Studio, portfolio companies can access product engineering, UX/UI, and go-to-market support at cost.
LP Network
Our LP base includes healthcare operators, clinicians, and industry leaders who actively support portfolio companies.
INVESTMENT PROCESS
How we assess a healthtech company
Founders deserve to know how a decision gets made before they spend months in a process. Ours is deliberately short, partner-led, and focused on the things that actually determine healthtech outcomes: evidence, regulation, and adoption.
First conversation
A single call with a partner, not an analyst screen. We want to understand the clinical problem, who pays for the solution, and what you have already validated. Most founders leave this call with a clearer view of their sequencing whether or not we invest.
Problem and evidence review
We test whether the claim you intend to make matches the evidence you can realistically generate. This covers clinical validation requirements, TGA and equivalent regulatory pathways, and whether your product scope creates avoidable regulatory exposure at this stage.
Adoption and commercial pathway
Healthcare buying cycles are long and rarely follow software norms. We map who signs, who blocks, and how the solution gets funded, then pressure test whether your go-to-market assumptions survive contact with a health service procurement process.
Reference and ecosystem checks
We speak with clinicians, health service operators, and researchers in our network who can assess whether the product is credible in practice. This is where specialist focus earns its keep: our references understand the domain, not just the pitch.
Investment committee and terms
Our Investment Committee reviews the full case. We aim to give a clear yes or no with reasoning, not an indefinite maybe. Where we pass, we say why, because that reasoning is often more useful to a founder than the cheque.
FOUNDER SUPPORT
What working with us looks like
Healthtech companies more often fail on sequencing than on ideas. Our role is to make sure what gets built first is strategically correct, and that ambition is matched to regulatory, clinical, and adoption reality.
Sequencing what gets built first
Most healthtech companies fail on sequencing, not on the idea. We help decide what belongs in the first release, what should wait until evidence exists, and what should never be built at all.
Regulatory and clinical literacy
We have navigated regulatory ambiguity and evidence requirements inside real health systems. That means practical guidance on claims, classification, and when a Software as a Medical Device pathway becomes unavoidable.
Enterprise health sales
Selling into hospitals, insurers, and primary care networks is a specific skill. We work through pilot design, procurement navigation, and pricing so early deals do not lock in unsustainable terms.
Product and engineering capacity
Through Dreamoro Studio, portfolio companies access product engineering, design, and data capability at cost, which extends runway during the period when hiring is hardest.
Mentoring, not monitoring
Our partners and advisors act as mentors and coaches to founders. The relationship is built around judgement and access rather than reporting obligations.
Follow-on and co-investment
We hold capacity for follow-on rounds and introduce portfolio companies to domestic and global co-investors who understand healthtech timelines.
LET'S TALK
Building in healthtech?
If you're a founder building technology that improves how healthcare is delivered, detected, or prevented, we'd love to hear your story.
Let's Talk